High Efficacy Halts ViiV HIV Prevention Study Early
ViiV Hopes Faster Cabotegravir Approval Will Be The Result
Prospects have improved for ViiV’s long-acting, injectable cabotegravir to be approved early for HIV prevention after a Phase III trial was stopped early due to efficacy.
You may also be interested in...
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.